Intrabodies as drug discovery tools and therapeutics

Current Opinion in Chemical Biology

Volumn 9, Issue 4, 2005, Pages 359-365

  Stocks, Martin ^a  

^a Iclectus Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INTRABODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY ISOLATION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; BIOMEDICINE; CELL SURFACE; CELL VIABILITY; CONSENSUS SEQUENCE; CYTOPLASM; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; ISOLATION PROCEDURE; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MOLECULE; NONHUMAN; REVIEW; SCREENING; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; TARGET CELL; VALIDATION PROCESS;

ANIMALS; ANTIBODIES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INTRACELLULAR SPACE; PROTEIN ENGINEERING;

EID: 22544471858     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2005.06.003     Document Type: Review

References (46)

1. K.H. Antman, and D.M. Livingston Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody Cell 19 1980 627 635
2. S. Biocca, M.S. Neuberger, and A. Cattaneo Expression and targeting of intracellular antibodies in mammalian cells EMBO J 9 1990 101 108
3. J.R. Carlson A new use for intracellular antibody expression: inactivation of human immunodeficiency virus type 1 Proc Natl Acad Sci USA 90 1993 7427 7428
4. W.A. Marasco, W.A. Haseltine, and S.Y. Chen Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody Proc Natl Acad Sci USA 90 1993 7889 7893
5. P. Wirtz, and B. Steipe Intrabody construction and expression III: engineering hyperstable V(H) domains Protein Sci 8 1999 2245 2250
6. ••], this paper led to the definition of a broadly applicable consensus framework for intrabody library generation. Using the 2-hybrid screening system described in [13] the two groups isolated several panels of intrabodies from diverse phage libraries and analysed the resulting structures. The isolated intrabodies were strikingly similar in their framework structures and allowed the authors to define a minimal sequence that could support intracellular folding.
7. ••].
8. A. Auf der Maur, D. Escher, and A. Barberis Antigen-independent selection of stable intracellular single-chain antibodies FEBS Lett 508 2001 407 412
9. E.C. Ohage, P. Wirtz, J. Barnikow, and B. Steipe Intrabody construction and expression. II. A synthetic catalytic Fv fragment J Mol Biol 291 1999 1129 1134
10. E. Ohage, and B. Steipe Intrabody construction and expression. I. The critical role of VL domain stability J Mol Biol 291 1999 1119 1128
11. T. Tanaka, M.N. Lobato, and T.H. Rabbitts Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies J Mol Biol 331 2003 1109 1120 The first reported use of human single variable domain fragments as intrabodies. This finding was slightly counterintuitive, as the general expectation was that the potential for the domains to have large exposed hydrophobic surfaces would make them unsuitable for intracellular expression. The heavy chain of a previously isolated scFv was found to have greater activity than the parent molecule. This led the authors to build a small library of single domains, based on the heavy chain, and isolated new clones from this library which were also superior in behaviour to the originating scFv.
12. T. Tanaka, G.T. Chung, A. Forster, M.N. Lobato, and T.H. Rabbitts De novo production of diverse intracellular antibody libraries Nucleic Acids Res 31 2003 e23
13. M. Visintin, E. Tse, H. Axelson, T.H. Rabbitts, and A. Cattaneo Selection of antibodies for intracellular function using a two-hybrid in vivo system Proc Natl Acad Sci USA 96 1999 11723 11728
14. A.A. der Maur, C. Zahnd, F. Fischer, S. Spinelli, A. Honegger, C. Cambillau, D. Escher, A. Pluckthun, and A. Barberis Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework J Biol Chem 277 2002 45075 45085 Selection of intrabodies achieved by screening a library built on a single framework that had been rigorously engineered to provide intracellular stability and function. This was the culmination of much work, refining the framework of an existing intrabody clone in an iterative manner to produce a framework with ideal properties for intracellular expression.
15. S. Fields, and O. Song A novel genetic system to detect protein-protein interactions Nature 340 1989 245 246
16. M.N. Lobato, and T.H. Rabbitts Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules Curr Mol Med 4 2004 519 528 A useful overview of the potential for therapeutic application of intrabodies.
17. M. Visintin, M. Quondam, and A. Cattaneo The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation Methods 34 2004 200 214
18. D.W. Colby, P. Garg, T. Holden, G. Chao, J.M. Webster, A. Messer, V.M. Ingram, and K.D. Wittrup Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display J Mol Biol 342 2004 901 912
19. F. Aires da Silva, M. Santa-Marta, A. Freitas-Vieira, P. Mascarenhas, I. Barahona, J. Moniz-Pereira, D. Gabuzda, and J. Goncalves Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity J Mol Biol 340 2004 525 542
20. F. Gennari, S. Mehta, Y. Wang, A. St Clair Tallarico, G. Palu, and W.A. Marasco Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation J Mol Biol 335 2004 193 207
21. R.W. Strube, and S.Y. Chen Enhanced intracellular stability of sFv-Fc fusion intrabodies Methods 34 2004 179 183
22. M. Visintin, G.A. Meli, I. Cannistraci, and A. Cattaneo Intracellular antibodies for proteomics J Immunol Methods 290 2004 135 153 A useful overview of the potential for application of intrabodies in drug discovery and R&D programmes.
23. K. Boonrod, D. Galetzka, P.D. Nagy, U. Conrad, and G. Krczal Single-chain antibodies against a plant viral RNA-dependent RNA polymerase confer virus resistance Nat Biotechnol 22 2004 856 862
24. T. Tanaka, and T.H. Rabbitts Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation EMBO J 22 2003 1025 1035
25. R.W. Strube, and S.Y. Chen Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies J Immunol Methods 263 2002 149 167
26. R. Zemel, Y. Berdichevsky, L. Bachmatov, I. Benhar, and R. Tur-Kaspa Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies J Hepatol 40 2004 1000 1007
27. M. Gal-Tanamy, R. Zemel, Y. Berdichevsky, L. Bachmatov, R. Tur-Kaspa, and I. Benhar HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen J Mol Biol 347 2005 991 1003
28. M. Figini, R. Ferri, D. Mezzanzanica, M. Bagnoli, E. Luison, S. Miotti, and S. Canevari Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies Gene Ther 10 2003 1018 1025
29. M. Popkov, N. Jendreyko, D.B. McGavern, C. Rader, and C.F. Barbas III Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody Cancer Res 65 2005 972 981
30. D.W. Colby, Y. Chu, J.P. Cassady, M. Duennwald, H. Zazulak, J.M. Webster, A. Messer, S. Lindquist, V.M. Ingram, and K.D. Wittrup Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody Proc Natl Acad Sci USA 101 2004 17616 17621
31. J.M. Lecerf, T.L. Shirley, Q. Zhu, A. Kazantsev, P. Amersdorfer, D.E. Housman, A. Messer, and J.S. Huston Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease Proc Natl Acad Sci USA 98 2001 4764 4769
32. A. Khoshnan, J. Ko, and P.H. Patterson Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity Proc Natl Acad Sci USA 99 2002 1002 1007
33. C. Zhou, S. Emadi, M.R. Sierks, and A. Messer A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein Mol Ther 10 2004 1023 1031
34. P. Paganetti, V. Calanca, C. Galli, M. Stefani, and M. Molinari β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide J Cell Biol 168 2005 863 868
35. F. Beyer, C. Doebis, A. Busch, T. Ritter, A. Mhashilkar, W.M. Marasco, H. Laube, H.D. Volk, and M. Seifert Decline of surface MHC I by adenoviral gene transfer of anti-MHC I intrabodies in human endothelial cells-new perspectives for the generation of universal donor cells for tissue transplantation J Gene Med 6 2004 616 623 An intriguing application of virally expressed intracellular antibody to prevent MHC expression in cells, which could be applicable to transplantation. This is a prime example of a retained intrabody being used to prevent the exit of a key membrane protein from its site of synthesis within the ER/golgi compartment, and thereby effecting a 'functional knockout' of the target protein.
36. J. Kurreck Expediting target identification and validation through RNAi Expert Opin Biol Ther 4 2004 427 429
37. K.K. Jain RNAi and siRNA in target validation Drug Discov Today 9 2004 307 309 A useful overview of the utilization of RNAi in the drug discovery world.
38. D. Vanhecke, and M. Janitz Functional genomics using high-throughput RNA interference Drug Discov Today 10 2005 205 212
39. J. Couzin Molecular biology RNAi shows cracks in its armor Science 306 2004 1124 1125 A warning shot across the bows of those relying on RNAi to solve all their problems.
40. Bilanges B, Stokoe D: Direct comparison of the specificity of gene silencing using antisense and RNAi. Biochem J 2005, in press.
41. K. Lundstrom Gene therapy applications of viral vectors Technol Cancer Res Treat 3 2004 467 477
42. M.E. Davis Non-viral gene delivery systems Curr Opin Biotechnol 13 2002 128 131
43. D. Dalkara, G. Zuber, and J.P. Behr Intracytoplasmic delivery of anionic proteins Mol Ther 9 2004 964 969
44. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat Rev Cancer 2 2002 750 763
45. A. Joliot, and A. Prochiantz Transduction peptides: from technology to physiology Nat Cell Biol 6 2004 189 196 A good overview of peptide-mediated transduction, its history and possible mechanisms of action.
46. M. Matsushita, and H. Matsui Protein transduction technology J Mol Med 83 2005 324 328